New Radiopharmaceuticals to Enter Market as R&D Activities Intensify Over the past few decades, immunology, biology, and genetics have progressed at a considerable pace due to which the development of cardiological, oncological, and neurological therapies has received a much-needed push. In the past 20 years, multiple radionuclide-based targeted therapies have gradually emerged as one of the most efficient techniques for inflammatory lesions and cancer treatment. At present, an array of therapeutic radionuclides, particularly β− emitters, is increasingly being used across clinics or tested in ongoing clinical trials. At present, within the radiopharmaceutical market , several studies are investigating the potential of 188Re for a broad range of therapeutic applications. Within the medical sector, the adoption of radiopharmaceuticals is at the nascent stage compared to that of other medicinal products and drugs. However, due to significant advancements and improvements...
Today, healthcare organizations operate in a dynamic ecosystem, wherein they are required to adopt unprecedented advancements for diagnostics and therapeutics, every now and then. Healthcare organizations are facing the uphill task to incorporate technological driven processes, and deliver managed care to the discerning consumer.